FDA Public Meeting: Evaluating Inclusion and Exclusion Criteria in Clinical Trials

The Food and Drug Administration (FDA) issued a Federal Register Notice to  announce a public meeting entitled “Evaluating Inclusion and Exclusion Criteria in Clinical Trials.” The purpose of the public meeting is to bring the stakeholder community together to discuss a variety of topics related to eligibility criteria in clinical trials and their potential impact on patient access to investigational drugs, and how to facilitate the enrollment of a diverse patient population. This meeting will be organized by the Duke-Robert J. Margolis, MD, Center for Health Policy at Duke University and is supported by a cooperative agreement with FDA.  The public meeting will be held on April 16, 2018, from 8:30 a.m. to 5 p.m. at the National Press Club, 529 14th St. NW, Washington, DC 20045.  See the supplementary information section in the Federal Register Notice for more information about the meeting and how to view the live webcast. You can also visit this website for additional travel and hotel information.